Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fecal Microbiota Transplantation (FMT) in for the Treatment of High-Risk Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT04139577 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04139577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04139577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fecal Microbiota Transplantation (FMT) in for the Treatment of High-Risk Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT)
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Completed
Start date
June 18, 2021
Completion date
January 5, 2023
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute graft-versus-host disease (gvhd) grade, fecal microbiota transplant, hematopoietic cell transplantation